9. Refeeding Syndrome

Quick Recap

Endocrine & Metabolic System, Protocol 9/9 — completing the Endocrine & Metabolic System.

1. Definition

Refeeding syndrome (RFS) = a severe, potentially FATAL metabolic response occurring after the reintroduction of nutrients following a period of starvation/inadequate intake — characterized by dangerous electrolyte shifts as metabolism switches from fat/protein catabolism back to carbohydrate metabolism.

2. At-Risk Populations

Nothing-by-mouth (NPO) for 7-10 days or longer; low BMI (<18.5 kg/m2); clinically relevant unintentional weight loss prior to admission (severity graded: mild <5%, moderate 5-10%, severe >10% weight loss over the preceding 3 months — this severity grading is a STRONG predictor of outcomes and should be actively elicited in nutrition history). Additional ICU-specific risk populations: congestive heart failure, mechanical ventilation, or patients prone to hypercapnia — these are less intuitive risk factors than the classic malnutrition/low-BMI picture and are easy to overlook.

Critical point: NO reliable clinical predictors of RFS have been identified — therefore, it is essential to consider ALL critically ill patients at risk, not just those with obvious malnutrition stigmata. This universalizes the vigilance requirement rather than allowing risk-based case-selection to create blind spots.

3. Pathophysiology

During starvation, the body shifts to fat/protein catabolism for energy, with relative depletion of intracellular phosphate, magnesium, and potassium stores (even though serum levels may appear deceptively normal, since these are predominantly intracellular ions and the body has been in a low-turnover state). Upon reintroduction of carbohydrate/nutrition:

• Insulin surges in response to carbohydrate load
• Insulin drives glucose, phosphate, magnesium, and potassium all INTRACELLULARLY simultaneously -> precipitous drops in SERUM levels of all three electrolytes
• Thiamine (vitamin B1) is consumed as a cofactor in carbohydrate metabolism (specifically in the pyruvate dehydrogenase and transketolase reactions) -> if thiamine stores were already marginal (common in malnutrition/alcoholism), refeeding can precipitate acute thiamine deficiency

Can occur after as little as 2 DAYS of nutritional restriction combined with reintroduction of dextrose-containing IV fluids or nutrition — the onset threshold is shorter than many clinicians assume, and even brief NPO periods with subsequent dextrose-containing fluid resumption can theoretically trigger it.

4. Incidence

Exact incidence is unknown given inconsistent definitions across studies, but an estimated 34-40% of at-risk patients develop hypophosphatemia (<0.65 mmol/L), and 4-10% develop SEVERE hypophosphatemia (<0.32 mmol/L) — far more common than the "rare syndrome" framing sometimes applied to it clinically.

5. Clinical Manifestations (Electrolyte-Driven)

Hypophosphatemia (the dominant, most-monitored derangement): symptoms typically occur only when serum phosphate <1 mg/dL, reflecting significant total body depletion — muscular weakness (INCLUDING THE DIAPHRAGM, a specific and dangerous manifestation that can precipitate respiratory failure/failure to wean from ventilation in an ICU patient), paresthesias, and in severe cases seizures, stupor, or coma.

Hypomagnesemia and hypokalemia co-occur via the same insulin-driven intracellular shift mechanism — arrhythmia risk, neuromuscular irritability/weakness.

Thiamine deficiency -> Wernicke-Korsakoff syndrome risk, particularly relevant in malnourished or alcohol-dependent patients — this is a DISTINCT complication from the electrolyte shifts and requires its own specific prophylactic strategy (Section 7).

6. Prevention and Monitoring — The Core Management Strategy

Given the absence of reliable predictors, ALL critically ill patients starting enteral or parenteral nutrition should have baseline AND DAILY serum phosphate levels followed for AT LEAST 3 DAYS or until normalized — this is a universal, not risk-stratified, monitoring recommendation, reflecting the "consider all critically ill patients at risk" principle from Section 2.

Increased monitoring while proactively replenishing thiamine and electrolytes (rather than waiting for derangement to manifest) is the recommended prevention strategy — RFS management is fundamentally about ANTICIPATION and proactive repletion, not purely reactive correction after derangement is detected.

7. Thiamine Prophylaxis

Assess Wernicke-Korsakoff syndrome risk specifically in malnourished or alcohol-use-disorder patients — early, AGGRESSIVE IV thiamine repletion should be used in higher-risk patients, ideally BEFORE or CONCURRENT with initiating carbohydrate-containing nutrition, since thiamine is consumed as nutrition/refeeding proceeds and a deficient patient can be acutely precipitated into Wernicke's encephalopathy by carbohydrate reintroduction without thiamine cover.

8. Nutrition Initiation Strategy

Comprehensive nutrition assessment on ICU admission and throughout the stay, including: nutrition-focused physical exam, diet history (SPECIFICALLY assessing recent intake to gauge RFS risk), biochemical data (complete metabolic panel, magnesium, phosphorus, CBC, targeted micronutrients), anthropometrics (height, weight, recent weight change with the severity grading from Section 2), functional status, and social history (food availability, alcohol use).

Plasma albumin and prealbumin are NOT recommended for nutritional status assessment — both are negative acute-phase reactants, meaning they are altered by critical illness/inflammation ITSELF (via changed synthesis/degradation and increased capillary losses) independent of actual nutritional status — a common clinical misconception worth explicitly correcting, since these markers are still sometimes reflexively checked/trended as nutrition indicators.

Emerging tool: serial bedside ultrasound measurement of skeletal muscle mass shows promise as an objective, practical tool for tracking muscle volume change over time, addressing the broader challenge that objective nutritional status assessment in the ICU is genuinely difficult.

9. Immediate Stabilization (ABCDE) — Once RFS Is Identified or Strongly Suspected

Circulation/Metabolic:

• Reduce or temporarily halt the rate of caloric/carbohydrate advancement if significant electrolyte derangement is detected — do not simply add repletion on top of an unchanged, potentially excessive feeding rate; slowing the metabolic drive itself is part of the correction strategy, not just chasing the resulting electrolyte losses
• Aggressively replete phosphate, magnesium, and potassium per their respective protocols (see Severe Electrolyte Disorders and Hyperkalemia protocols for detailed dosing; note hypokalemia repletion follows standard principles not covered in the hyperkalemia-focused protocol, but the same careful, monitored IV administration approach applies)
• Give IV thiamine (typically before or with the first carbohydrate load in at-risk patients, per Section 7) rather than waiting for neurologic signs to emerge

Checklist:

10. Phosphate Repletion (Cross-Reference, Full Detail in Severe Electrolyte Disorders Protocol)

Formulation: potassium phosphate if normal renal function and K+ <4; sodium phosphate if renal impairment or K+ >4. If hypotension occurs during infusion, suspect hypocalcemia and discontinue. Reduce dosing 33% in severe renal failure. Transition to oral once phosphate >1.5 mg/dL; 24-36h of repletion often needed to replenish intracellular stores.

RFS-specific consideration in Total Parenteral Nutrition electrolyte prescribing: standard TPN electrolyte content should be actively ADJUSTED upward for potassium, phosphate, and magnesium specifically in the setting of refeeding (per standard TPN electrolyte reference ranges: potassium 40-120 mEq/day, phosphate 10-30 mM/day, magnesium 8.1-24.3 mEq/day, with "refeeding" explicitly listed as a condition requiring alteration of the standard amount provided for all three).

11. Organ Support

Careful, monitored electrolyte repletion (phosphate, magnesium, potassium); IV thiamine; adjusted/slowed nutritional advancement rate during active derangement; respiratory support if diaphragmatic weakness from severe hypophosphatemia contributes to ventilatory failure or failure to wean.

12. Consultation Matrix

13. Monitoring Framework

Daily phosphate (minimum) for >=3 days or until normalized upon nutrition initiation in ALL ICU patients; magnesium and potassium trended alongside; glycemic control monitoring (insulin surge component); respiratory status/diaphragmatic strength assessment if severe hypophosphatemia; ongoing nutrition-focused physical exam and weight trend rather than albumin/prealbumin.

14. Complications

Severe hypophosphatemia with respiratory muscle weakness/failure to wean, cardiac arrhythmia (hypokalemia/hypomagnesemia), seizures/coma (severe electrolyte derangement), Wernicke-Korsakoff syndrome (unrecognized thiamine deficiency), metastatic calcification/hypocalcemia from overaggressive phosphate repletion. Prevention: universal RFS risk consideration and baseline/daily monitoring, proactive (not reactive) thiamine and electrolyte repletion, adjusted nutrition advancement rate during derangement. Rescue: standard electrolyte-specific repletion protocols, respiratory support for diaphragmatic weakness, IV thiamine for evolving Wernicke's signs.

15. Escalation & De-escalation

Escalate: significant electrolyte derangement detected during monitoring -> slow/hold nutrition advancement, aggressive repletion per standard protocols, escalate monitoring frequency.

De-escalate: electrolytes stable through the 3-day+ monitoring window, nutrition advancing without further derangement -> resume standard advancement rate, transition to routine nutrition monitoring, discontinue enhanced electrolyte surveillance.

16. ICU Discharge Criteria

Electrolytes stable through the monitoring window, nutrition successfully advanced to goal without recurrent derangement, thiamine repletion completed in at-risk patients, no evidence of Wernicke-Korsakoff syndrome, nutrition plan established for ongoing care.

17. Documentation & Medicolegal Checklist

18. Key Guidelines

Compher C, Bingham AL, McCall M, et al. Guidelines for the provision of nutrition support therapy in the adult critically ill patient: ASPEN. JPEN J Parenter Enteral Nutr. 2022;46(1):12-41.

19. Landmark Evidence

Crook M. Refeeding syndrome: problems with definitions and management. Nutrition. 2014;30(11-12):1448-1455 — highlights the definitional inconsistency underlying the uncertain incidence estimates. Heyland D, Patel J, Compher C, et al. EFFORT Protein trial. Lancet. 2023;401:568-576 — relevant broader ICU nutrition/protein dosing evidence context.

20. Controversies

The lack of validated clinical predictors for RFS is itself a genuine, acknowledged evidence gap — current practice defaults to universal vigilance rather than risk-stratified monitoring precisely because no reliable predictive model exists. Optimal nutrition advancement rate/caloric restriction strategy specifically for RFS prevention (vs standard ICU nutrition advancement protocols) is not rigidly standardized across guidelines. The precise phosphate threshold and monitoring duration (3 days cited, but individualized extension "until normalized") reflects a pragmatic rather than RCT-derived recommendation.

21. References

1. Nutrition Support in Critical Illness (Refeeding Syndrome section). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 76).
2. Compher C, Bingham AL, McCall M, et al. Guidelines for the provision of nutrition support therapy in the adult critically ill patient: ASPEN. JPEN J Parenter Enteral Nutr. 2022;46(1):12-41.
3. Crook M. Refeeding syndrome: problems with definitions and management. Nutrition. 2014;30(11-12):1448-1455.
4. Disorders of Plasma Sodium, Potassium, Calcium, Magnesium, and Phosphorus chapter (hypophosphatemia treatment table). Washington Manual of Critical Care, 4th ed, 2025 (Ch. 26).
5. Heyland D, Patel J, Compher C, et al. EFFORT Protein trial. Lancet. 2023;401:568-576.

See also: Severe Electrolyte Disorders (Endocrine & Metabolic System) for the full phosphate/magnesium repletion dosing detail this protocol references.